Monoclonal antibody treatment of colorectal cancer

British Journal of Surgery

Volumn 84, Issue 11, 1997, Pages 1511-1517

  Pullyblank, A M ^a   Monson, J R T ^a  

^a UNIVERSITY OF HULL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOLOGICAL ADJUVANT; MONOCLONAL ANTIBODY;

ADJUVANT THERAPY; CANCER IMMUNOTHERAPY; COLORECTAL CANCER; DRUG EFFICACY; HUMAN; PRIORITY JOURNAL; REVIEW; ANTIBODY THERAPY; ANTINEOPLASTIC ACTIVITY; CANCER INHIBITION; CHIMERA; CLINICAL TRIAL; DRUG ANALYSIS; DRUG COMBINATION; IMMUNOTHERAPY; MONOCLONAL ANTIBODY THERAPY; MULTICENTER STUDY; NEOPLASTIC CELL TRANSFORMATION; NONHUMAN; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; SOLID TUMOR; THERAPY;

ANTIBODIES, MONOCLONAL; COLORECTAL NEOPLASMS; HUMANS; IMMUNOTHERAPY;

EID: 0030724328     PISSN: 00071323     EISSN: None     Source Type: Journal    
DOI: 10.1002/bjs.1800841106     Document Type: Review

References (106)

1. Kohler G, Milstein D. Continuous cultures of fused cells producing antibodies of predefined specificity. Nature 1975; 256: 495-7.
2. Steplewski Z, Lubeck MD, Koprowski H. Human macrophages armed with murine immunoglobulin G2a antibodies to tumors destroy human cancer cells. Science 1983; 221: 865-7.
3. Kipps TJ, Parham P, Punt J, Herzenberg LA. Importance of immunoglobulin isotype in human antibody-dependent cell-mediated cytotoxicity directed by murine monoclonal antibodies. J Exp Med 1985; 161: 1-17.
4. Ortaldo J, Woodhouse C, Morgan AC, Herberman RB, Cheresh DA, Reisfeld R. Analysis of effector cells in human antibody-dependent cellular cytotoxicity with murine monoclonal antibodies. J Immunol 1987; 138: 3566-72.
5. Graziano RF, Fanger MW. FcγRI and FcγRII on monocytcs and granulocytes are cytotoxic trigger molecules for tumour cells. J Immunol 1987; 139: 3536-41.
6. Herlyn D, Koprowski H. IgG2a monoclonal antibodies inhibit tumour growth through interaction with effector cells. Proc Natl Acad Sci U S A 1982; 79: 4761-5.
7. Dippold WG, Lloyd KO, Li T, Ikeda H, Oettgen HF, Old LJ. Cell surface antigens of human malignant melanoma: definition of 6 antigenic systems with mouse monoclonal antibodies. Proc Natl Acad Sci U S A 1980; 77: 6114-18.
8. Hakomori S, Kannagi R. Glycosphingolipids as tumour-associated and differentiation markers. J Natl Cancer Inst 1983; 71: 231-4.
9. Stramignoni D, Bowen R, Atkinson B, Schlom J. Differential reactivity of monoclonal antibodies with human colon adenocarcinomas and adenomas. Int J Cancer 1983; 31: 543-52.
10. Harper JR, Bumol TF, Reisfeld RA. Characterization of monoclonal antibody 155.8 and partial characterization of its proteoglycan antigen on human melanoma cells. J Immunol 1984; 132: 2096-104.
11. Kohwi Y, Hellstrom I, Hakomori S, Hellstrom KE. Amphipathic lipid bound protein antigens in mouse bladder carcinomas detected by a monoclonal antibody. Biochemistry 1984; 23: 5945-50.
12. Wang JY, Tang R, Chiang JM. Value of carcinoembryonic antigen in the management of colorectal cancer. Dis Colon Rectum 1994; 37: 272-7.
13. Begent RHJ. The value of carcinoembryonic antigen in clinical practice. Br J Hosp Med 1987; 37: 335-8.
14. Herlyn M, Steplewski Z, Herlyn D, Kowprowski H. Colorectal carcinoma-specific antigens: detection by means of monoclonal antibodies. Prof Natl Acad Sci U S A 1979; 76: 1438-42.
15. Gottlinger H, Johnson J, Reithmuller G. Biochemical and epitope analysis of the 17-1A membrane antigen. Hybridoma 1986; 5: S29-37.
16. Ross AH, Lubeck M, Steplewski Z, Kowprowski H. Identification and characterization of the CO17-1A carcinoma-associated antigen. Hybridoma 1986; 5: S21-8.
17. Steplewski Z, Chang TH, Herlyn M, Kowprowski H. Release of monoclonal antibody-defined antigens by human colorectal carcinoma and melanoma cells. Cancer Res 1981; 41: 2723-7.
18. Shen J-W, Atkinson B. Kowprowski H, Sears HF. Binding of murine immunoglobulin to human tissues after immunotherapy with anticolorectal carcinoma monoclonal antibody. Int J Cancer 1984; 33: 465-8.
19. Gottlinger HG, Funke I, Johnson JP, Gokel JM, Reithmuller G. The epithelial cell surface antigen 17-1A, a target for antibody mediated tumour therapy: its biochemical nature, tissue distribution and recognition by different monoclonal antibodies. Int J Cancer 1986; 38: 47-53.
20. Dionne L. The pattern of blood-borne metastasis from carcinoma of rectum. Cancer 1965; 18: 775-81.
21. McGinnis LS. Surgical treatment options for colorectal cancer. Cancer 1994; 74(Suppl): 2147-50.
22. Muir CS, Parkin DM. The world cancer burden: prevention or perish. BMJ 1985; i: 5-6.
23. Silverberg E, Holleb A. Major trends in cancer: 25 year survey. Cancer 1975; 25: 1-8.
24. Simon JB. Occult blood screening for colorectal carcinoma: a critical review. Gastroenterology 1985; 88: 820-37.
25. Hart AR, Wicks ACB, Mayberry JF. Colorectal cancer screening in asymptomatic populations. Gut 1995; 36: 590-8.
26. August DA, Ottow RT, Sugarbaker PH. Clinical perspectives on human colorectal cancer metastases. Cancer Metastasis Rev 1984; 3: 303-24.
27. Leather AJM, Kocjan G, Savage F et al. Detection of free malignant cells in the peritoneal cavity before and after resection of colorectal cancer. Dis Colon Rectum 1994; 37: 814-19.
28. Schlimok G, Funke I, Bock B, Schweiberer B, Witte J, Reithmuller G. Epithelial tumour cells in bone marrow of patients with colorectal cancer. Immunocytochemical detection, phenotypic characterization and prognostic significance. J Clin Oncol 1990; 8: 831-7.
29. Lindemann F, Schlimok G, Dirschedl P, Witte J, Reithmuller G. Prognostic significance of micrometastatic tumour cells in bone marrow of colorectal cancer patients. Lancet 1992; 340: 685-9.
30. Forman WB. The role of chemotherapy and adjuvant therapy in the management of colorectal cancer. Cancer 1994; 74: 2151-3.
31. Moertel CG, Fleming TR, Macdonald JS et al. Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma. N Engl J Med 1990; 322: 352-8.
32. Pantel K, Braun S, Schlimok G, Reithmuller G. Micrometastatic tumour cells in bone marrow in colorectal cancer. Lancet 1993; 341: 501.
33. Pantel K, Schlimok G, Braun S et al. Differential expression of proliferation associated molecules in individual micrometastatic carcinoma cells. J Natl Cancer Inst 1993; 17: 1419-24.
34. Kalofonos HP, Stewart S, Epenetos AA. Antibody-guided diagnosis and therapy of malignant lesions. Int J Cancer 1988; 2(Suppl): 74-80.
35. Martin EW, Tuttle SE, Rousseau M et al. Radioimmunoguided surgery: intraoperative use of monoclonal antibody 17-1A in colorectal cancer. Hybridoma 1986; 5: S97-108.
36. v. Wussow P, Spitler L, Block B, Deicher H. Immunotherapy in patients with advanced malignant melanoma using an anti melanoma antibody ricin A immunotoxin. Eur J Cancer Clin Oncol 1988; 24: S69-73.
37. Steplewski Z. Wistar symposium on immunodiagnosis and immunotherapy with CO17-1A MAb in gastrointestinal cancer. Hybridoma 1986; 5(Suppl): 1.
38. Neville AM, Gusterson BA. Monoclonal antibodies and human tumours; pathological and clinical aspects. Eur J Cancer Clin Oncol 1985; 21: 355-69.
39. Neal CE, Swan TL, Baker MR, Ellis RL, Katterhagen JG. Immunoscintigraphy of colorectal carcinoma utilizing 111-In-labelled monoclonal antibody conjugate CYT-103. Gastrointest Radiol 1991; 16: 251-5.
40. Doerr RJ, Anbdel-Nabi H, Krag D, Mitchell E. Radiolabelled antibody imaging in the management of colorectal cancer. Ann Surg 1991; 214: 118-24.
41. Byers VS, Baldwin RW. Therapeutic strategies with monoclonal antibodies and immunoconjugates. Immunology 1988; 65: 329-35.
42. Rosenberg R. Passive immunotherapy of cancer in animals and man. Adv Cancer Res 1977; 35: 323-88.
43. Lindstrom BA. An experimental study of myelotoxic sera: therapeutic attempts in myeloid leukaemia. Acta Medica Scandinavica Suppl 1927; 22: 1769-75.
44. Pressman D, Korngald L. The in vivo localization of anti-Wagner osteogenic sarcoma antibodies. Cancer 1953; 6: 619-25.
45. Sears H, Atkinson B, Mattis J et al. Phase I clinical trial of monoclonal antibody in treatment of gastrointestinal tumours. Lancet 1982; i: 762-5.
46. Blottiere H, Maural C, Douillard J. Immune function of patients with gastrointestinal carcinoma after treatment with multiple infusions of monoclonal antibody 17-1A. Cancer Res 1987; 47: 5238-41.
47. Sears H, Herlyn O, Steplewski Z, Kowprowski H. Initial trial use of murine monoclonal antibodies as immunotherapeutic agents for gastrointestinal carcinoma. Hybridoma 1986; 5: S109-15.
48. Dillman RO, Shawler DL, Dillman JB, Royston I. Therapy of a chronic lymphocytic leukaemia and cutaneous T cell lymphoma with T101 monoclonal antibody. J Clin Oncol 1984; 2: 881-91.
49. D3 ganglioside: a phase I trial in patients with malignant melanoma. Proc Natl Acad Sci USA 1985; 82: 1242-6.
50. D2 specific monoclonal antibody 3F8: a phase I study in patients with neuroblastoma and malignant melanoma. J Clin Oncol 1987; 5: 1430-40.
51. LoBuglio AF, Saleh MN, Lee J et al. Phase I trial of multiple large doses of murine monoclonal antibody CO17-1A. I. Clinical aspects. J Natl Cancer Inst 1988; 80: 932-6.
52. Pimm M, Perkins A, Armitage N, Baldwin RW. The characteristics of blood borne radiolabels and the effect of anti-mouse IgG antibodies on the localization of monoclonal antibody in cancer patients. J Nucl Med 1985; 26: 1011-23.
53. Sears H, Herlyn D, Steplewski Z, Kowprowsky H. Effects of monoclonal antibody immunotherapy on patients with gastrointestinal adenocarcinoma. Journal of Biological Response Modifiers 1984; 47: 2727-32.
54. Frodin J-E, Lefvert A-K, Mellstedt H. Pharmacokinetics of the mouse monoclonal antibody 17-1A in cancer patients receiving various treatment schedules. Cancer Res 1990; 50: 4866-71.
55. Scheinberg DA. Current applications of monoclonal antibodies for the therapy of hematopoietic cancers. Curr Opin Immunol 1991; 3: 679-84.
56. Reithmuller G, Johnson OP. Monoclonal antibodies in the detection and therapy of micrometastatic epithelial cancers. Curr Opin Immunol 1992; 4: 647-55.
57. Verrill H, Goldberg M, Rosenbaum R et al. Clinical trial of Wistar Institute 17-1A monoclonal antibody in patients with advanced gastrointestinal adenocarcinoma: a preliminary report. Hybridoma 1986; 5: S175-83.
58. Frodin J-E, Harmenberg U, Biberfeld P et al. Clinical effects of monoclonal antibodies (MAb 17-1A) in patients with metastatic colorectal carcinomas. Hybridoma 1986; 7: 309-21.
59. Reithmuller G, Schneider-Gadicke E, Schlimock G et al. and the German Cancer Aid 17-1A Study Group. Randomised trial of monoclonal antibody for adjuvant therapy of resected Dukes' C colorectal carcinoma. Lancet 1994; 343: 1177-83.
60. Morrison SL, Johnson MJ, Herzenberg LA, Vernon TO. Chimeric human antibody molecules: mouse antigen-binding domains with human constant region domains. Proc Natl Acad Sci U S A 1984; 81: 6851-5.
61. Sun LK, Curtis P, Rakowicz-Szulczynska E et al. Chimeric antibodies with 17-1A-derived variable and human constant regions. Hybridoma 1986; 5: S17-20.
62. Shaw DR, Khazaeli MB, Sun LK et al. Characterization of a mouse/human chimeric monoclonal antibody (17-1A) to a colon cancer tumour-associated antigen. J Immunol 1987; 138: 4534-8.
63. Liu AY, Robinson RR, Hellstrom KE, Murray D, Chang P, Hellstrom I. Chimeric mouse-human IgG1 antibody that can mediate lysis of cancer cells. Proc Natl Acad Sci U S A 1987; 84: 3439-43.
64. Liu A, Robinson R, Murray E et al. Production of a mouse-human chimeric monoclonal antibody to CD20 with potent Fc-dependent biologic activity. J Immunol 1987; 139: 3521-6.
65. Nishimura Y, Yokayama M, Araki K, Ueda R, Kudo A, Watanabe T. Recombinant human-mouse chimeric monoclonal antibody specific for common acute lymphocyte leukaemia antigen. Cancer Res 1987; 47: 999-1005.
66. Masucci G, Lindemalm C, Frodin J-E, Hagstrom B, Mellstedt H. Effects of human blood mononuclear cell populations in antibody dependent cellular cytotoxicity (ADCC) using two murine (CO17-1A and Br55-2) and one chimeric (17-1A) monoclonal antibodies against a human colorectal cell line (SW948). Hybridoma 1988; 7: 429-40.
67. LoBuglio AF, Wheeler RH, Trang J et al. Mouse/human chimeric monoclonal antibody in man: kinetics and immune response. Proc Natl Acad Sci U S A 1989; 86: 4220-4.
68. Pullyblank AM, Guillou PJ, Monson JRT. m17-1A, c17-1A and cSF25-mediated antibody-dependent cell-mediated cytotoxicity in patients with advanced cancer. Br J Cancer 1994; 70: 753-8.
69. Jerne NK. Towards a network theory of the immune system. Annales D'Immunol (Paris) 1974; 125: 373-89.
70. Kowprowski H, Herlyn D, Lubeck MD, Defreitas E, Sears HF. Human anti-idiotype antibodies in cancer patients: is the modulation of the immune response beneficial for the patient? Proc Natl Acad Sci U S A 1984; 81: 216-19.
71. 3) lead to tumour regression after mAb therapy? Cancer Immunol Immunother 1993; 37: 264-70.
72. 3) of importance for tumour response to mAb therapy? Cancer Immunol Immunother 1994; 38: 149-59.
73. Khazaeli MB, Saleh MN, Wheeler RH et al. Phase I trial of multiple large doses of murine monoclonal antibody CO17-1A. II: Pharmacokinetics and immune response. J Natl Cancer Inst 1988; 80: 937-42.
74. Shawler DL, Bartholomew RM, Smith LM, Dillman RO. Human immune response to multiple injections of murine monoclonal IgG. J Immunol 1985; 135: 1530-5.
75. Saleh MN, LoBuglio AF, Wheeler RH et al. A phase II trial of murine monoclonal antibody 17-1A and interferon-γ: clinical and immunological data. Cancer Immun Immunother 1990; 32: 185-90.
76. Velders MP, Litvinov SV, Warnaar SO et al. New chimeric anti-pancarcinoma monoclonal antibody with superior cytotoxicity-mediating potency. Cancer Res 1994; 54: 1753-9.
77. Herlyn D, Herlyn M, Ross AH, Ernst C, Atkinson B, Kowprowski H. Efficient selection of human tumor growth-inhibiting monoclonal antibodies. J Immunol Methods 1984; 73: 157-67.
78. Herlyn D, Sears HF, Ernst CS, Iliopoulos D, Steplewski Z, Kowprowski H. Initial clinical evaluation of two murine IgG2a monoclonal antibodies for immunotherapy of gastrointestinal carcinoma. Am J Clin Oncol 1991; 14: 371-8.
79. Herlyn D, Somasundaram R, Zaloudik J et al. Anti-idiotype and recombinant antigen in immunotherapy of colorectal cancer. Cell Biophys 1994; 24/25: 143-53.
80. Fogler WE, Klinger MR, Abraham KG, Gottlinger HG, Reithmuller G, Daddona PE. Enhanced cytotoxicity against colon carcinoma by combinations of noncompeting monoclonal antibodies to the 171-1A antigen. Cancer Res 1988; 48: 6303-8.
81. Wilson B, Ozturk M, Takahashi H et al. Cell-surface changes associated with transformation of human hepatocytes to the human phenotype. Proc Natl Acad Sci U S A 1988; 85: 3140-4.
82. Takahashi H, Wilson B, Ozturk M et al. In vivo localization of human colon adenocarcinoma by binding to a highly expressed cell surface antigen. Cancer Res 1988; 48: 6573-9.
83. Takahashi H, Carlson R, Ozturk M et al. Radioimmunolocation of hepatic and pulmonary metastasis of human colon adenocarcinoma (MAb SF-25). Gastroenterology 1989; 96: 1317-29.
84. Pullyblank AM, Guillou PJ, Monson JRT. Interleukin-1β and tumour necrosis factor-α may be responsible for the lytic mechanism during antigen tumour ADCC. Br J Cancer 1995; 172: 601-6.
85. Nelson H, Ramsey PS, McKeann DJ, Dozois RR, Donohue JH. Anti-tumour x anti-lymphocyte heteroconjugates augment colon tumour cell lysis in vitro and prevent tumour growth in vivo. Dis Colon Rectum 1991; 34: 140-7.
86. Mack M, Reithmuller G, Kufer P. A small bispecific antibody construct expressed as a functional single-chain molecule with high tumour cell cytotoxicity. Proc Natl Acad Sci U S A 1995; 92: 7021-5.
87. Reid I, Lundy J, Donahue JH. Enhancement of in-vitro tumour-infiltrating lymphocyte cytotoxicity by heteroconjugated antibodies. J Immunol 1992; 148: 2630-5.
88. Reid I, Lundy J, Monson JRT et al. Heteroconjugated antibodies enhance lymphocyte-mediated tumour cell lysis in vitro and in vivo. Br J Surg 1992; 79: 628-32.
89. Sega DM, Wunderlich J Jr. Targeting of cytotoxic cells with heterocrosslinked antibodies. Cancer Invest 1988; 6: 83-92.
90. de Palazzo IG, Gercel-Taylor C, Kitson J, Weiner LM. Potentiation of tumor lysis by a bispecific antibody that binds to CA19-1 antigen and the Fcγ receptor expressed by human large granular lymphocytes. Cancer Res 1990; 50: 7123-8.
91. Pardoll DM. Cancer vaccines. Immunol Today 1993; 14: 310-16.
92. Skolnick AA. 'Essential components now in place' for clinical testing of cancer vaccine strategies, experts say. JAMA 1995; 273: 528-30.
93. Aden M, Tsang KY. Monoclonal antibodies and their role in the modulation of the immune response. J Surg Oncol 1993; 54: 103-8.
94. Dorudi A, Northover JMA, Vile RG. Gene transfer therapy in cancer. Br J Surg 1993; 80: 566-72.
95. Robins RA, Denton GWL, Hardcastle JD, Austin EB, Baldwin RW, Durrant LG. Anti-tumour immune response and interleukin 2 production induced in colorectal cancer patients by immunization with human monoclonal anti-idiotypic antibody. Cancer Res 1991; 51: 5425-9.
96. Verstovsek S, Macubbin D, Ehrke MJ, Mihich E. Tumoricidal activation of murine resident peritoneal macrophages by interleukin 2 and tumour necrosis factor α. Cancer Res 1992; 52: 3880-5.
97. Vuist WMJ, Buitenen F, Hekman A, Melief CJM. Two distinct mechanisms of anti-tumour activity mediated by the combination of interleukin 2 and monoclonal antibodies. Cancer Res 1990; 50: 5767-72.
98. Schultz KR, Klarnet FP, Peace DJ et al. Monoclonal antibody therapy of murine lymphoma: enhanced efficacy by concurrent administration of interleukin 2 or lymphokine activated killer cells. Cancer Res 1990; 50: 5421-5.
99. Massucci G, Wersall P, Nielsen J, Nielsen HK. Mellstedt H. Lymphokine activated killer (LAK) cells in antibody dependent cellular cytotoxicity (ADCC) using MAb 17-1A: a combination of potential usefulness in tumour therapy. Hybridoma 1989; 8: 507-16.
100. Fan S, Fehr H-O, Adams D. Activation of macrophages for ADCC in vitro: effects of IL-4, TNF, interferons-α/β and GM-CSF. Cell Immunol 1991; 135: 78-87.
101. Ralph P, Nakoinz I, Rennick D. Role of interleukin 2, interleukin 4 and α, β and γ interferon in stimulating macrophage antibody-dependent tumoricidal activity. J Exp Med 1988; 167: 712-17.
102. Weiner LM, Moldofsky PJ, Gatenby RA et al. Antibody delivery and effector cell activation in a phase II trial of recombinant γ-interferon and the murine monoclonal antibody CO17-1A in advanced colorectal carcinoma. Cancer Res 1988; 48: 2568-73.
103. Saleh MN, LoBuglio AF, Wheeler RH et al. A phase II trial of murine monoclonal antibody 17-1A and interferon-γ: clinical and immunological data. Cancer Immunol Immunother 1990; 32: 185-90.
104. Weiner LM, Steplewski Z, Kowprowski H, Sears H, Litwin S, Comis RL. Biologic effects of gamma interferon pretreatment followed by monoclonal antibody 17-1A administration in patients with gastrointestinal carcinoma. Hybridoma 1986; 5: S65-77.
105. Ragnhammar P, Fagerberg J, Frodin J-E et al. Effect of monoclonal antibody 17-1A and GM-CSF in patients with advanced colorectal carcinoma - long lasting complete remissions can be induced. Int J Cancer 1993; 53: 751-8.
106. Mellstedt H, Frodin JE, Raghammar P et al. Therapy of colorectal carcinoma with monoclonal antibodies (Mab 17-1A) alone or in combination with granulocyte monocyte-colony stimulating factor (GM-CSF). Acta Oncol 1991; 30: 923-31.